On September 19, the pharmaceutical equipment company Tailin Bio released the investor relations activity record form, and the company accepted a survey
of 1 institution on the same day.
In the question-and-answer session, the agency asked questions
about the company's main competitors, the current market competition, and the current construction progress of the "Cell Therapy Industrialization Equipment Manufacturing Base Project".
Among them, in view of the company's main competitors and the current market competition, Tailin Biology replied that the company's similar products have fewer domestic competitors, while the product prices and after-sales service capabilities of foreign competitors are basically not competitive compared with the company, so the company has a strong competitive advantage
in microbial testing and sterilization equipment and other products.
Up to now, the bidding, auction and listing of the construction land of the "Cell Therapy Industrialization Equipment Manufacturing Base Project" has not yet entered the substantive work of the listing stage, and there is no clear time for the time
being.
In order to ensure the smooth implementation of the fundraising project, the company also actively communicated with the relevant departments of the local government and formulated alternative measures
in the event that the land for the fundraising project could not be obtained as planned.
According to reports, the main business of Tailin Biology is the research and development, manufacturing and sales
of pharmaceutical equipment such as microbial detection and control technology system products and organic matter analysis instruments.
The company is committed to life sciences, medical engineering, biosecurity and analytical instruments and other product research and development and technological innovation, is a systematic solution provider
in the field of biomedical engineering.
The company has always practiced the mission of "serving human health and benefiting the world", focusing on the main theme of the life and health industry, deeply cultivating the research and development and production of high-end equipment and consumables in the fields of pharmaceutical engineering, cell engineering, medical engineering, bio-environmental protection engineering, etc.
, and providing system service solutions
.
At present, the number of customers of the company has reached thousands, covering pharmaceutical enterprises, food and drug inspection and quarantine and supervision and management agencies, medical and health institutions, scientific research and other fields
.
It is worth mentioning that since 2022, Tailin Bio has received many batches of institutional research
.
For example, on January 5, Tailin Bio released the investor relations activity record form, and the company accepted 8 institutional surveys on January 5, 2022; On February 17, Tailin Bio issued an announcement that 3 institutions investigated the company
on February 17, 2022.
From the perspective of the pharmaceutical equipment industry to which the company belongs, the current environment of the entire pharmaceutical equipment industry, including market demand, policies and other factors, has brought a new round of opportunities
to the head enterprises.
CITIC Securities once mentioned in the research report that the global pharmaceutical equipment industry is constantly iterating with the progress of downstream treatment technology, and the commercialization potential of emerging technologies represented by cell gene therapy and multi-specific drugs is huge, which is expected to drive the rapid expansion of upstream demand for global biopharmaceuticals and catalyze the further transformation
of head enterprises into integrated full-process service providers.
Galaxy Securities also pointed out in the research report that combined with the perspective of policy, fundamentals and asset allocation, pharmaceutical equipment in the pharmaceutical field may have better performance, and the policy immunity sector in medicine is mainly concentrated in the upstream, including pharmaceutical equipment will benefit
.
According to the Tailin Biological Report, the company achieved a total operating income of 146 million yuan in the first half of 2022, an increase of 31.
2% year-on-year; Achieved net profit attributable to the mother of 31.
3 million yuan, an increase of 13.
2% year-on-year; Earnings per share were RMB0.
38
.
